Archived explainer. For the current picture see today's HROW page.
HARROW INC (HROW) is drawing unusual attention today. Our newswire has captured 2 stories on HROW across 1 source in the last 36 hours, with AI sentiment reading bullish (avg 61/100).
HROW stock is moving higher today, with the stock up 3.5% in early trading. The rise follows the presentation of new clinical data at the ASRS 2026 Annual Meeting, which highlights growing support for Harrow’s products IHEEZO and BYOOVIZ. These developments are drawing attention to the company’s expanding ophthalmology portfolio and its partnerships with Samsung Bioepis.
Harrow Inc. presented interim data from a post-marketing surveillance study on SB11 (BYOOVIZ/AMELIVU), a biosimilar to Lucentis, showing improvements in best-corrected visual acuity and central subfield thickness in treatment-naïve patients. The data was shared alongside updates on IHEEZO, a low-viscosity ocular anesthetic gel, where a 150-patient study compared it to subconjunctival lidocaine. Harrow also noted that its QUELL trial is enrolling 236 subjects, with topline results expected in Q4 2026.
The company’s partnership with Samsung Bioepis continues to be a focal point, with the biosimilar BYOOVIZ now commercially available. These updates reinforce Harrow’s position in the ophthalmology space and build on recent product launches and clinical progress.
HROW has a market cap of $1.7 billion and remains unprofitable with a trailing twelve-month EPS of -0.40. However, revenue has grown by 26.2% TTM, and the stock is trading within its 52-week range of $28.54 to $54.85. Insiders have been active in recent weeks, with four buy transactions totaling $469,000 reported in the last 90 days. The stock has a beta of 0.25, indicating low volatility relative to the market.
Investors should monitor the topline results from the QUELL trial in Q4 2026, which could provide further validation for IHEEZO and influence the stock’s momentum.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
Treatment-naïve patients showed mean BCVA and CST improvements of -0.10 and -95 µm, while follow-up lasted up to 24 weeks after dosing.
An interim study of 150 patients compared IHEEZO with subconjunctival lidocaine; QUELL is enrolling about 236 subjects, with topline data expected Q4 2026.
More on HROW: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier HROW move explainers: 2026-07-27 · 2026-07-21 · 2026-07-20